SLC5A2 and cardiac arrhythmia: Our study represents the inaugural demonstration that SGLT2 inhibitors reduce arrhythmias caused by oncology treatment arrythmia (RR 0.34, 95% CI 0.23, 0.50, P < 0.0001, I2 = 70%).